BioNano Genomics (NASDAQ: BNGO) is one of 24 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare BioNano Genomics to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.
Valuation & Earnings
This table compares BioNano Genomics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioNano Genomics||$12.00 million||-$18.50 million||-1.49|
|BioNano Genomics Competitors||$1.14 billion||$146.65 million||14.07|
BioNano Genomics’ competitors have higher revenue and earnings than BioNano Genomics. BioNano Genomics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares BioNano Genomics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioNano Genomics Competitors||-235.98%||-26.73%||-12.21%|
Insider & Institutional Ownership
11.0% of BioNano Genomics shares are held by institutional investors. Comparatively, 60.8% of shares of all “Analytical instruments” companies are held by institutional investors. 14.3% of shares of all “Analytical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings for BioNano Genomics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioNano Genomics Competitors||165||864||1235||64||2.51|
BioNano Genomics presently has a consensus price target of $11.50, suggesting a potential upside of 194.87%. As a group, “Analytical instruments” companies have a potential downside of 4.77%. Given BioNano Genomics’ stronger consensus rating and higher possible upside, research analysts plainly believe BioNano Genomics is more favorable than its competitors.
BioNano Genomics Company Profile
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its instruments and consumables for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in North America, Europe, the Middle East, India, Africa, and the Asia Pacific. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.